Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.00 | 9.00 | 0.10% |
| CAC 40 | 7,726.09 | 36.51 | -0.47% |
| DAX 40 | 23,954.83 | 85.09 | -0.35% |
| Dow JONES (US) | 45,442.08 | 194.82 | -0.43% |
| FTSE 100 | 9,206.21 | 10.61 | -0.12% |
| HKSE | 25,077.62 | 78.80 | 0.32% |
| NASDAQ | 21,485.21 | 219.95 | -1.01% |
| Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
| NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
| S&P 500 | 6,459.33 | 42.53 | -0.65% |
| S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
| SSE Composite Index | 3,857.93 | 14.33 | 0.37% |